Xarelto, a Janssen Pharmaceuticals product, was found to be more effective in preventing reoccurring blood clots than aspirin, a recent study suggests. Under the Bayer-funded study, 1.2% and 1.5% of patients taking varying dosages of the drug experienced a reoccurring blood clot, compared with 4.4% of patients who taking aspirin. Cardiologists not involved in the global study welcomed the results, and are looking forward to continued research into affordable blood clot prevention alternatives. Read the full article here.